Sara Ciullini Mannurita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara Ciullini Mannurita has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Fanelli
General Laboratory, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy
7 shared publications - Francesca Romano
General Laboratory, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy
7 shared publications - Edda Russo
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
5 shared publications - Valentina Becherucci
Clinical Pathology Laboratory, Santa Maria Annunziata Hospital, 50134 Florence, Italy
4 shared publications - Alessandra Mongia
General Laboratory, Careggi University Hospital, Florence, Italy
3 shared publications - Anna Maria Grazia Gelli
Clinical Pathology Laboratory Unit, S. Giuseppe Hospital, Azienda USL Toscana Centro, 50053 Empoli, Italy
3 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3397
Hidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework addressing four complementary domains: analytical validity, biological validity, clinical validity, and clinical utility. The evidence required in each domain depends on the intended claim and clinical use.
- 19 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3397
Open AccessHidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework addressing four complementary domains: analytical validity, biological validity, clinical validity, and clinical utility. The evidence required in each domain depends on the intended claim and clinical use.
- Open Access
- 24 September 2026
- Published by MDPI AG in Preprints.org
Hidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework in which additional AI-detected electrophoretic features progress through analytical validity, biological validity, clinical validity, and clinical utility before being considered actionable laboratory information.
- 24 September 2026
- Published by MDPI AG in Preprints.org
Open AccessHidden Signals in Serum Protein Electrophoresis: Artificial Intelligence from Laboratory Pattern Recognition to Clinical Validation
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework in which additional AI-detected electrophoretic features progress through analytical validity, biological validity, clinical validity, and clinical utility before being considered actionable laboratory information.
- Open Access
- 19 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (16) , 2642
Beyond Analytical Agreement: Integrating Analytical Performance and Algorithm-Assisted Morphological Interpretation in a Comparative Evaluation of the Mindray BC-7800/BC-7900 and Sysmex XN-9100 Hematology Platforms
Background/Objectives: Modern automated hematology analyzers combine quantitative cell counting with proprietary algorithms for automated morphological interpretation. While analytical validation traditionally focuses on measurement agreement, less attention has been paid to the evaluation of algorithm-assisted morphological interpretation. This study compared the analytical performance and automated morphological flagging of the Sysmex XN-9100 and Mindray BC-7800/BC-7900 platforms under routine laboratory conditions. Methods: A total of 183 peripheral blood samples collected between October 2025 and February 2026 were analyzed in parallel using both platforms. The study population included healthy individuals and patients with hematological and non-hematological disorders. Analytical agreement for complete blood count (CBC) and leukocyte differential parameters was assessed using Passing–Bablok regression and Bland–Altman analyses. Automated morphological flagging was evaluated in 157 samples using expert optical microscopy as the reference standard. McNemar’s test, Cohen’s kappa coefficient, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. Results: Excellent agreement was observed for the principal CBC parameters, including white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, and platelet count (correlation coefficients: 0.981–1.000), with minimal proportional bias. Greater variability was found for monocytes, eosinophils, and basophils, particularly at low cell concentrations. Although analytical performance was highly comparable, the two platforms showed different morphological flagging profiles. Both analyzers achieved high negative predictive values (>90%), while differences in sensitivity and specificity across individual flag categories reflected distinct algorithm-assisted classification strategies. Agreement with expert microscopy ranged from fair to moderate for most pathological flags. Conclusions: The Mindray BC-7800/BC-7900 and Sysmex XN-9100 demonstrated excellent analytical agreement for routine CBC testing. However, comparable analytical performance did not necessarily correspond to identical automated morphological interpretation. These results indicate that evaluation of modern hematology analyzers should include both analytical performance and agreement between automated flags and expert microscopy.
- 19 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (16) , 2642
Open AccessBeyond Analytical Agreement: Integrating Analytical Performance and Algorithm-Assisted Morphological Interpretation in a Comparative Evaluation of the Mindray BC-7800/BC-7900 and Sysmex XN-9100 Hematology Platforms
Background/Objectives: Modern automated hematology analyzers combine quantitative cell counting with proprietary algorithms for automated morphological interpretation. While analytical validation traditionally focuses on measurement agreement, less attention has been paid to the evaluation of algorithm-assisted morphological interpretation. This study compared the analytical performance and automated morphological flagging of the Sysmex XN-9100 and Mindray BC-7800/BC-7900 platforms under routine laboratory conditions. Methods: A total of 183 peripheral blood samples collected between October 2025 and February 2026 were analyzed in parallel using both platforms. The study population included healthy individuals and patients with hematological and non-hematological disorders. Analytical agreement for complete blood count (CBC) and leukocyte differential parameters was assessed using Passing–Bablok regression and Bland–Altman analyses. Automated morphological flagging was evaluated in 157 samples using expert optical microscopy as the reference standard. McNemar’s test, Cohen’s kappa coefficient, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. Results: Excellent agreement was observed for the principal CBC parameters, including white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, and platelet count (correlation coefficients: 0.981–1.000), with minimal proportional bias. Greater variability was found for monocytes, eosinophils, and basophils, particularly at low cell concentrations. Although analytical performance was highly comparable, the two platforms showed different morphological flagging profiles. Both analyzers achieved high negative predictive values (>90%), while differences in sensitivity and specificity across individual flag categories reflected distinct algorithm-assisted classification strategies. Agreement with expert microscopy ranged from fair to moderate for most pathological flags. Conclusions: The Mindray BC-7800/BC-7900 and Sysmex XN-9100 demonstrated excellent analytical agreement for routine CBC testing. However, comparable analytical performance did not necessarily correspond to identical automated morphological interpretation. These results indicate that evaluation of modern hematology analyzers should include both analytical performance and agreement between automated flags and expert microscopy.
- Open Access
- 29 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2387
Real-World Evaluation of the Sysmex XN-9100 WDF–WPC Workflow: Diagnostic Performance, False-Negative Burden, and Potential Optimization of Smear Review Workload
Background: Modern hematology analyzers integrate multiparametric technologies and adaptive flagging algorithms to support rapid detection of abnormal leukocyte populations. The Sysmex XN-9100 employs the White Blood Cell Differential (WDF) channel for first-line screening and the White Precursor Cell (WPC) channel as a reflex test for improved detection of blasts and abnormal lymphocytes. Although widely implemented, the real-world diagnostic performance and workflow implications of this integrated strategy remain incompletely characterized. Objectives: To evaluate, in a large real-world cohort, the performance of the Sysmex XN-9100 WDF–WPC workflow, focusing on its diagnostic accuracy, its capability to identify pathological cases within the WDF-negative population, and its potential implications for blood smear review workload optimization. Methods: A retrospective analysis was performed on 4531 consecutive routine blood samples reviewed between February and June 2025. All samples were analyzed using the Sysmex XN-9100. WDF-positive cases (“Blasts/Abnormal lymphocytes?”) underwent reflex WPC testing (“Blasts?” and “Abnormal lymphocytes?”). Peripheral blood smear morphology, based on the evaluation of 200 leukocytes using the DI-60 digital imaging system, constituted the reference standard. Diagnostic performance metrics, including sensitivity, specificity, predictive values, likelihood ratios, accuracy, and ROC analysis, were calculated for WDF and WPC channels using both individual and aggregated flag evaluations. Results: The WDF-B/AL (White Blood Cell Differential Channel-“Blasts/Abnormal lymphocytes?”) flag demonstrated high sensitivity (88.24%) and negative predictive value (92.73%), supporting its role as an effective first-line screening tool, although specificity was limited (48.87%; AUC = 0.75). Unlike most previous studies, our workflow allowed evaluation of pathological cases occurring within the WDF-negative population, providing a realistic estimate of the false-negative burden. Disaggregated WPC analysis revealed complementary diagnostic profiles: WPC-B (White Precursor Cell Channel-“Blasts?”) showed higher specificity (77.71%) and overall discriminative performance (AUC = 0.81), whereas WPC-AL (White Precursor Cell Channel-“Abnormal lymphocytes?”) achieved higher sensitivity (92.18%) and negative predictive value (95.99%). Aggregated evaluation of WPC flags (logical OR) maximized sensitivity (92.68%) and reduced false-negative cases, supporting the role of the WPC channel as a second-level diagnostic safety net. Furthermore, within the integrated laboratory workflow, WPC-negative results may support the optimization of manual smear-review allocation when interpreted together with predefined institutional smear-review criteria, while maintaining diagnostic safety. Conclusions: The Sysmex XN-9100 WDF–WPC workflow constitutes a multilayered high-sensitivity screening strategy that prioritizes abnormality detection while optimizing laboratory efficiency. The complementary behavior of WPC-B and WPC-AL enhances overall workflow safety, whereas evaluation of WDF-negative pathological cases provides a more realistic assessment of screening performance than conventional reflex-based studies. Beyond analytical accuracy, the workflow may contribute to balancing diagnostic reliability, patient safety, and resource utilization in high-volume laboratory practice.
- 29 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2387
Open AccessReal-World Evaluation of the Sysmex XN-9100 WDF–WPC Workflow: Diagnostic Performance, False-Negative Burden, and Potential Optimization of Smear Review Workload
Background: Modern hematology analyzers integrate multiparametric technologies and adaptive flagging algorithms to support rapid detection of abnormal leukocyte populations. The Sysmex XN-9100 employs the White Blood Cell Differential (WDF) channel for first-line screening and the White Precursor Cell (WPC) channel as a reflex test for improved detection of blasts and abnormal lymphocytes. Although widely implemented, the real-world diagnostic performance and workflow implications of this integrated strategy remain incompletely characterized. Objectives: To evaluate, in a large real-world cohort, the performance of the Sysmex XN-9100 WDF–WPC workflow, focusing on its diagnostic accuracy, its capability to identify pathological cases within the WDF-negative population, and its potential implications for blood smear review workload optimization. Methods: A retrospective analysis was performed on 4531 consecutive routine blood samples reviewed between February and June 2025. All samples were analyzed using the Sysmex XN-9100. WDF-positive cases (“Blasts/Abnormal lymphocytes?”) underwent reflex WPC testing (“Blasts?” and “Abnormal lymphocytes?”). Peripheral blood smear morphology, based on the evaluation of 200 leukocytes using the DI-60 digital imaging system, constituted the reference standard. Diagnostic performance metrics, including sensitivity, specificity, predictive values, likelihood ratios, accuracy, and ROC analysis, were calculated for WDF and WPC channels using both individual and aggregated flag evaluations. Results: The WDF-B/AL (White Blood Cell Differential Channel-“Blasts/Abnormal lymphocytes?”) flag demonstrated high sensitivity (88.24%) and negative predictive value (92.73%), supporting its role as an effective first-line screening tool, although specificity was limited (48.87%; AUC = 0.75). Unlike most previous studies, our workflow allowed evaluation of pathological cases occurring within the WDF-negative population, providing a realistic estimate of the false-negative burden. Disaggregated WPC analysis revealed complementary diagnostic profiles: WPC-B (White Precursor Cell Channel-“Blasts?”) showed higher specificity (77.71%) and overall discriminative performance (AUC = 0.81), whereas WPC-AL (White Precursor Cell Channel-“Abnormal lymphocytes?”) achieved higher sensitivity (92.18%) and negative predictive value (95.99%). Aggregated evaluation of WPC flags (logical OR) maximized sensitivity (92.68%) and reduced false-negative cases, supporting the role of the WPC channel as a second-level diagnostic safety net. Furthermore, within the integrated laboratory workflow, WPC-negative results may support the optimization of manual smear-review allocation when interpreted together with predefined institutional smear-review criteria, while maintaining diagnostic safety. Conclusions: The Sysmex XN-9100 WDF–WPC workflow constitutes a multilayered high-sensitivity screening strategy that prioritizes abnormality detection while optimizing laboratory efficiency. The complementary behavior of WPC-B and WPC-AL enhances overall workflow safety, whereas evaluation of WDF-negative pathological cases provides a more realistic assessment of screening performance than conventional reflex-based studies. Beyond analytical accuracy, the workflow may contribute to balancing diagnostic reliability, patient safety, and resource utilization in high-volume laboratory practice.
- Open Access
- 25 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 661
Diagnostic Performance of Leukocyte Abnormality Detection in a Large Cohort of Healthy Blood Donors Using Sysmex XN Series Analyzers Integrated with Peripheral Blood Morphology and Flow Cytometry
Background: The Sysmex XN series (XN-1000 and XN-9100, Sysmex Corporation, Kobe, Japan) represents a latest-generation automated hematology platform integrating fluorescence-based technologies and multi-channel analysis (WDF and WPC) to improve leukocyte characterization. This study aimed to evaluate the performance of the Sysmex XN series in detecting leukocyte abnormalities flagged during routine complete blood count analysis in a large cohort of healthy donors, using morphological assessment and flow cytometry as confirmatory methods. Methods: Approximately 8000 healthy blood donors from the AOU Meyer Transfusion Centre were evaluated between 2021 and 2024. All samples underwent CBC analysis using the XN-1000 and XN-9100 analyzers with the WDF channel. Samples showing WBC-related flags were subjected to reflex testing with the WPC channel, followed by digital blood smear review using the DI-60 system (CellaVision, Lund, Sweden) and flow cytometric immunophenotyping. Results: WDF flags for “blasts/abnormal lymphocytes” were identified in 23 samples. Two samples were negative on WPC analysis as well as on morphological and flow cytometric evaluation. Among the remaining cases, WPC analysis identified flags for abnormal lymphocytes, atypical lymphocytes, or blasts, which were variably associated with reactive changes, transient immune activation, or clonal lymphoproliferative conditions. In one donor, monoclonal B-cell lymphocytosis was diagnosed by flow cytometry. Overall, reactive morphological features confirmed by flow cytometry were observed in approximately 50% of flagged cases. Conclusions: WPC analysis provides relevant additional diagnostic information and demonstrates higher specificity compared with the WDF channel alone; however, it does not fully resolve all instrument-generated flags, confirming the essential role of morphological assessment. Interestingly, the frequent occurrence of inflammatory profiles in recently vaccinated donors suggests that transient immune activation may influence leukocyte flagging. Larger studies are warranted to further investigate this association and to optimize the diagnostic performance of the WPC channel in donor screening.
- 25 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 661
Open AccessDiagnostic Performance of Leukocyte Abnormality Detection in a Large Cohort of Healthy Blood Donors Using Sysmex XN Series Analyzers Integrated with Peripheral Blood Morphology and Flow Cytometry
Background: The Sysmex XN series (XN-1000 and XN-9100, Sysmex Corporation, Kobe, Japan) represents a latest-generation automated hematology platform integrating fluorescence-based technologies and multi-channel analysis (WDF and WPC) to improve leukocyte characterization. This study aimed to evaluate the performance of the Sysmex XN series in detecting leukocyte abnormalities flagged during routine complete blood count analysis in a large cohort of healthy donors, using morphological assessment and flow cytometry as confirmatory methods. Methods: Approximately 8000 healthy blood donors from the AOU Meyer Transfusion Centre were evaluated between 2021 and 2024. All samples underwent CBC analysis using the XN-1000 and XN-9100 analyzers with the WDF channel. Samples showing WBC-related flags were subjected to reflex testing with the WPC channel, followed by digital blood smear review using the DI-60 system (CellaVision, Lund, Sweden) and flow cytometric immunophenotyping. Results: WDF flags for “blasts/abnormal lymphocytes” were identified in 23 samples. Two samples were negative on WPC analysis as well as on morphological and flow cytometric evaluation. Among the remaining cases, WPC analysis identified flags for abnormal lymphocytes, atypical lymphocytes, or blasts, which were variably associated with reactive changes, transient immune activation, or clonal lymphoproliferative conditions. In one donor, monoclonal B-cell lymphocytosis was diagnosed by flow cytometry. Overall, reactive morphological features confirmed by flow cytometry were observed in approximately 50% of flagged cases. Conclusions: WPC analysis provides relevant additional diagnostic information and demonstrates higher specificity compared with the WDF channel alone; however, it does not fully resolve all instrument-generated flags, confirming the essential role of morphological assessment. Interestingly, the frequent occurrence of inflammatory profiles in recently vaccinated donors suggests that transient immune activation may influence leukocyte flagging. Larger studies are warranted to further investigate this association and to optimize the diagnostic performance of the WPC channel in donor screening.
- Open Access
- 27 June 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (3) , 413-420
A Rare Onset of T-Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by bone marrow expansion and the proliferation of one or more myeloid cell lineages, predominantly driven by the expression of the constitutively active fusion product tyrosine kinase BCR:ABL1. Rarely, CML patients directly develop a blast crisis (BC), mostly of myeloid origin. CML at blast crisis with a T-cell phenotype at diagnosis, without any prior history of CML, is extremely rare. Herein, we describe one rare CML case, in a young man showing an unusual and early T-lymphoid blastic crisis at diagnosis, as the first onset of a previously unknown CML. The multidisciplinary collaboration between laboratorians and clinicians for the diagnosis and management of this atypical case was crucial in outlining both a targeted pharmacological treatment and a successful hematopoietic stem cell transplantation.
- 27 June 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (3) , 413-420
Open AccessA Rare Onset of T-Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by bone marrow expansion and the proliferation of one or more myeloid cell lineages, predominantly driven by the expression of the constitutively active fusion product tyrosine kinase BCR:ABL1. Rarely, CML patients directly develop a blast crisis (BC), mostly of myeloid origin. CML at blast crisis with a T-cell phenotype at diagnosis, without any prior history of CML, is extremely rare. Herein, we describe one rare CML case, in a young man showing an unusual and early T-lymphoid blastic crisis at diagnosis, as the first onset of a previously unknown CML. The multidisciplinary collaboration between laboratorians and clinicians for the diagnosis and management of this atypical case was crucial in outlining both a targeted pharmacological treatment and a successful hematopoietic stem cell transplantation.
- Open Access
- 27 March 2024
- Published by MDPI AG in Preprints.org
A Rare Onset of T Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations
In chronic myeloid leukemia (CML), a clonal proliferative disorder of granulocytic lineage, the 90%‐95% of cases are characterized by t(9;22) (q34.1;q11.2) translocation, leading to the Philadelphia chromosome (1). Rarely, CML patients directly present a blast crisis, mostly of myeloid origin (2, 3). Herein, we describe one rare CML case, showing an unusual early T lymphoid blastic crisis.
- 27 March 2024
- Published by MDPI AG in Preprints.org
Open AccessA Rare Onset of T Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations
In chronic myeloid leukemia (CML), a clonal proliferative disorder of granulocytic lineage, the 90%‐95% of cases are characterized by t(9;22) (q34.1;q11.2) translocation, leading to the Philadelphia chromosome (1). Rarely, CML patients directly present a blast crisis, mostly of myeloid origin (2, 3). Herein, we describe one rare CML case, showing an unusual early T lymphoid blastic crisis.
- Open Access
- 21 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 349-363
Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies
IKAROS is a transcription factor forming homo- and heterodimers and regulating lymphocyte development and function. Germline mutations affecting the IKAROS N-terminal DNA binding domain, acting in a haploinsufficient or dominant-negative manner, cause immunodeficiency. Herein, we describe 4 germline heterozygous IKAROS variants affecting its C-terminal dimerization domain, via haploinsufficiency, in 4 unrelated families. Index patients presented with hematologic disease consisting of cytopenias (thrombocytopenia, anemia, neutropenia)/Evans syndrome and malignancies (T-cell acute lymphoblastic leukemia, Burkitt lymphoma). These dimerization defective mutants disrupt homo- and heterodimerization in a complete or partial manner, but they do not affect the wild-type allele function. Moreover, they alter key mechanisms of IKAROS gene regulation, including sumoylation, protein stability, and the recruitment of the nucleosome remodeling and deacetylase complex; none affected in N-terminal DNA binding defects. These C-terminal dimerization mutations are largely associated with hematologic disorders, display dimerization haploinsufficiency and incomplete clinical penetrance, and differ from previously reported allelic variants in their mechanism of action. Dimerization mutants contribute to the growing spectrum of IKAROS-associated diseases displaying a genotype-phenotype correlation.
- 21 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 349-363
Open AccessGermline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies
IKAROS is a transcription factor forming homo- and heterodimers and regulating lymphocyte development and function. Germline mutations affecting the IKAROS N-terminal DNA binding domain, acting in a haploinsufficient or dominant-negative manner, cause immunodeficiency. Herein, we describe 4 germline heterozygous IKAROS variants affecting its C-terminal dimerization domain, via haploinsufficiency, in 4 unrelated families. Index patients presented with hematologic disease consisting of cytopenias (thrombocytopenia, anemia, neutropenia)/Evans syndrome and malignancies (T-cell acute lymphoblastic leukemia, Burkitt lymphoma). These dimerization defective mutants disrupt homo- and heterodimerization in a complete or partial manner, but they do not affect the wild-type allele function. Moreover, they alter key mechanisms of IKAROS gene regulation, including sumoylation, protein stability, and the recruitment of the nucleosome remodeling and deacetylase complex; none affected in N-terminal DNA binding defects. These C-terminal dimerization mutations are largely associated with hematologic disorders, display dimerization haploinsufficiency and incomplete clinical penetrance, and differ from previously reported allelic variants in their mechanism of action. Dimerization mutants contribute to the growing spectrum of IKAROS-associated diseases displaying a genotype-phenotype correlation.
- 1 October 2017
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 17 (5) , 317-324
Novel molecular defects associated with very early-onset inflammatory bowel
Immune dysregulation disorders present with common clinical features of multiorgan autoimmunity. Gastrointestinal involvement is the hallmark of an impaired immune homeostasis. This review will give an overview on the novel phenotypes, highlighting the major points that will help to enable early diagnosis and treatment. The rapid progress on DNA sequencing technologies have led to the identification of monogenic defects that adversely impact the control of immune homeostasis. Lymphocytes may be present but dysfunctional, allowing for the development of excessive autoreactivity and resultant autoimmune disease. Regulatory T cells (Tregs) play an essential role in enforcing immune tolerance. Here we illustrate disorders caused by impairment of mechanisms ensuring Tregs function (Tregs related) in which autoimmunity is a hallmark of the clinical disease presentation and other disorders, affecting molecules more broadly involved in immune responses and indirectly causing immune dysregulation (Tregs unrelated). Clinical presentation is sometime mischievous and often symptoms are analogous in different diseases and can mislead diagnosis. The increasing comprehension of immunological concepts behind immune dysregulation diseases will allow better and in some cases possibly even targeted treatment. A genetic diagnosis therefore becomes important information in this group of patients, especially as some patients might require hematopoietic stem cell transplantation.
- 1 October 2017
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 17 (5) , 317-324
Novel molecular defects associated with very early-onset inflammatory bowel
Immune dysregulation disorders present with common clinical features of multiorgan autoimmunity. Gastrointestinal involvement is the hallmark of an impaired immune homeostasis. This review will give an overview on the novel phenotypes, highlighting the major points that will help to enable early diagnosis and treatment. The rapid progress on DNA sequencing technologies have led to the identification of monogenic defects that adversely impact the control of immune homeostasis. Lymphocytes may be present but dysfunctional, allowing for the development of excessive autoreactivity and resultant autoimmune disease. Regulatory T cells (Tregs) play an essential role in enforcing immune tolerance. Here we illustrate disorders caused by impairment of mechanisms ensuring Tregs function (Tregs related) in which autoimmunity is a hallmark of the clinical disease presentation and other disorders, affecting molecules more broadly involved in immune responses and indirectly causing immune dysregulation (Tregs unrelated). Clinical presentation is sometime mischievous and often symptoms are analogous in different diseases and can mislead diagnosis. The increasing comprehension of immunological concepts behind immune dysregulation diseases will allow better and in some cases possibly even targeted treatment. A genetic diagnosis therefore becomes important information in this group of patients, especially as some patients might require hematopoietic stem cell transplantation.
- 31 August 2017
- Published by Morressier GmbH
ANALYSIS OF GUT MICROBIOTA IN PRIMARY IMMUNODEFICIENCIES AND IMMUNE DYSREGULATION SYNDROMES
- 31 August 2017
- Published by Morressier GmbH
ANALYSIS OF GUT MICROBIOTA IN PRIMARY IMMUNODEFICIENCIES AND IMMUNE DYSREGULATION SYNDROMES